The H1 reports of Chinese listed companies in 2022 have all been revealed. Read More >

Stock price review: centralized procurement VS epidemic, differentiated growth and excess earnings. Two peaks in January 2022 and March-April 2022. IVD, low-value consumables, etc. performed prominently, mainly driven by the epidemic... Read More >

FDA has issued an emergency use authorization for both the Pfizer-BioNTech and Moderna bivalent COVID-19 boosters. Read More >

The use of biomarker and genetic tests during pregnancy is now extremely widespread. But what if both parents’ genes were broadly analyzed for possible risks prior to conception?... Read More >

On September 1, Nanjing Vazyme Biotech Co.,Ltd. signed a strategic cooperation agreement with Henan Medical Biological Testing Company. Read More >

BGI Genomics said on Thursday that it has received CE-IVD marking for its next-generation sequencing-based test for thalassemia mutation detection.... Read More >

Novo Nordisk’s $1.1 billion acquisition of Forma Therapeutics is intended to expand its sickle cell and rare blood disorder portfolio. Read More >

Wanzijian medical testing is a medical diagnosis service section newly established by Orient Gene last year, as well as a key strategic layout section for Orient Gene to conduct industrial upgrading from “a product provider” to “a product provider + a third-party testing servi... Read More >

Biocartis on Thursday reported a 21 percent year-over-year increase in revenues for the first half of 2022 as higher collaboration revenue offset a decline in SARS-CoV-2 product sales.... Read More >

SkylineDx said on Thursday that it has obtained CE-IVD marking for its Merlin Assay to predict which melanoma patients are at low risk of nodal metastasis.... Read More >